Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Bioregnum channel feed
Dems fire off a silly pricing bill; What's wrong with Novartis?
9 years ago
Opinion
Put away the flamethrower Mr. President. We come in peace and prosperity.
9 years ago
Opinion
Trump needs to prove he's serious about science; PTC's latest move is a jaw dropper
9 years ago
Opinion
Bristol-Myers makes a decisive move to fix its R&D problem; Let's not underestimate Trump now
9 years ago
Opinion
The new CEOs in biopharma are joining the big players at the billion-dollar chip table
9 years ago
Opinion
There has to be a better way to handle Duchenne drugs; Let's get to the bottom of the Juno debacle
9 years ago
Opinion
Let's not forget why biopharma megamergers are such an awful idea
9 years ago
Opinion
Another price-gouging CEO proves the system is broken, underscoring need for principled reform at the FDA
9 years ago
Opinion
No, President Trump, biopharma does not want you to deregulate drug development
9 years ago
Opinion
Another biotech games the system, and everyone gets to pay for the fallout
9 years ago
Opinion
Vowing to help, Trump manages to spark an angry protest against policies and a plan to revamp the FDA
9 years ago
Opinion
AstraZeneca chief is betting the company’s future on a single roll of the dice
9 years ago
Opinion
Big Pharma CEOs get a face-to-face with Trump and a shot at a negotiated cease fire
9 years ago
Opinion
M&A is off to a hot start in 2017; Too bad we can't say the same for gender parity
9 years ago
Opinion
Libertarian ideas on FDA deregulation threaten biotech; It's time for some real power to reform drug prices, reasonably
9 years ago
Opinion
Mallinckrodt just got its hand slapped for illegally protecting an 85,000% price hike
9 years ago
Opinion
Trump nukes biopharma, and the fallout is radioactive
9 years ago
Opinion
2017 gets started with a bang as we get a glimpse of the good, the bad and the ugly
9 years ago
Opinion
The Senate fumbles its first stab at pharma profiteering, keeping the issue front and center in 2017
9 years ago
Opinion
Big Pharma’s business model is broken; New drug OKs plunged this year, highlighting an ugly reality
9 years ago
Opinion
Drug pricing remains the big issue for 2017; Let's not go down the rabbit hole at the FDA
9 years ago
Opinion
Is the US biopharma industry headed for a turning point in 2017?
9 years ago
Pharma
Opinion
21st Century Cures Act could use a second look; It's time for the FDA to open up
9 years ago
Opinion
Juno and the FDA screwed up. People died. What now?
9 years ago
Opinion
First page
Previous page
11
12
13
14
15
16
Next page
Last page